Key result
Sodium citrate, unlike EDTA, reveals higher in vitro platelet adhesiveness in IHD versus healthy controls.
Why the study?
Does the choice of anticoagulant (sodium citrate vs EDTA) affect the measurement of in vitro platelet adhesiveness in patients with ischaemic heart disease compared to healthy subjects?
Case-Control
Does the choice of anticoagulant (sodium citrate vs EDTA) affect the measurement of in vitro platelet adhesiveness in patients with ischaemic heart disease compared to healthy subjects?
The choice of anticoagulant significantly impacts in vitro platelet adhesiveness measurements, with sodium citrate revealing differences between ischaemic heart disease patients and healthy subjects that EDTA obscures.
Answers are grounded in this paper and cite their sources.
Anticoagulant choice may influence detection of platelet differences in ischaemic heart disease; leaves open whether sodium citrate better reflects pathophysiology.
Platelet adhesiveness was measured in vitro in a group of patients with ischaemic heart disease and in a group of matched healthy subjects using either 1% EDTA or 3.8% sodium citrate as anticoagulant. When sodium citrate was used platelet adhesiveness was significantly greater in the group with ischaemic heart disease. However, no difference was found when EDTA was used. In both groups platelet adhesiveness was found to be significantly greater with sodium citrate than with EDTA.
No takes yet. Share an insight, caveat, or question.
Paul J. Nestel (1961) conducted a case-control in Ischaemic heart disease. Ischaemic heart disease vs. Matched healthy subjects was evaluated on Platelet adhesiveness in vitro. In vitro platelet adhesiveness was significantly greater in patients with ischaemic heart disease compared to healthy subjects when using sodium citrate, but not when using EDTA.
Synapse has enriched 10 related papers. Consider them for comparative context: